(Total Views: 373)
Posted On: 11/19/2020 9:45:17 PM
Post# of 36566
haha...just trying to keep up with you...
Here is one more -
Global Roundup: Two Big Deals Highlighting Biopharma Growth in China and More
Published: Nov 19, 2020 By Alex Keown
In addition to the Pfizer and LianBio focus on China, Florida-based Generex Biotechnology closed a $50 million licensing and development agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology. The fee provides for the exclusive use of the Ii-Key vaccine platform for infectious disease and cancer in China and its territories. The agreement includes the first Ii-Key platform project for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China, with a $5 million upfront licensing fee, 100% funding for manufacturing, development and commercial registration, a $20 million success fee for approval Ii-Key- SARS-CoV-2 vaccine in China, and royalty payments for COVID vaccine sales in China with the potential to reach several billion dollars, the company said.
https://www.biospace.com/article/biospace-glo...up-nov-19/
________________
DocJ wrote -
Thanks Paul, you have been finding some good stuff lately!
Read More: https://investorshangout.com/post/newpost/622...z6eIc6uOIn
Here is one more -
Global Roundup: Two Big Deals Highlighting Biopharma Growth in China and More
Published: Nov 19, 2020 By Alex Keown
In addition to the Pfizer and LianBio focus on China, Florida-based Generex Biotechnology closed a $50 million licensing and development agreement with a consortium of partners in China for the Ii-Key vaccine platform technology from Generex subsidiary NuGenerex Immuno-Oncology. The fee provides for the exclusive use of the Ii-Key vaccine platform for infectious disease and cancer in China and its territories. The agreement includes the first Ii-Key platform project for the development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China, with a $5 million upfront licensing fee, 100% funding for manufacturing, development and commercial registration, a $20 million success fee for approval Ii-Key- SARS-CoV-2 vaccine in China, and royalty payments for COVID vaccine sales in China with the potential to reach several billion dollars, the company said.
https://www.biospace.com/article/biospace-glo...up-nov-19/
________________
DocJ wrote -
Thanks Paul, you have been finding some good stuff lately!
Read More: https://investorshangout.com/post/newpost/622...z6eIc6uOIn
(1)
(0)
